Premium
ADDITION OF LENALIDOMIDE TO R‐CHOP (R2CHOP) IMPROVES OUTCOMES IN NEWLY DIAGNOSED DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL): FIRST REPORT OF ECOG‐ACRIN1412 A RANDOMIZED PHASE 2 US INTERGROUP STUDY OF R2CHOP VS R‐CHOP
Author(s) -
Nowakowski G.S.,
Hong F.,
Scott D.W.,
Macon R.,
King R.L.,
Habermann T.M.,
WagnerJohnston N.,
Casulo C.,
Wade J.L.,
Nagargoje G.G.,
Reynolds C.M.,
Cohen J.B.,
Khan N.,
Amengual J.,
Richards K.L.,
Little R.F.,
Leonard J.P.,
Friedberg J.W.,
Kostakoglu L.,
Kahl B.S.,
Witzig T.E.
Publication year - 2019
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.6_2629
Subject(s) - lenalidomide , diffuse large b cell lymphoma , medicine , hazard ratio , clinical endpoint , international prognostic index , oncology , febrile neutropenia , progression free survival , phases of clinical research , regimen , chemotherapy regimen , neutropenia , lymphoma , randomized controlled trial , confidence interval , chemotherapy , multiple myeloma